Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.
暂无分享,去创建一个
Rubén M. Maggio | Rubén M Maggio | S. Vignaduzzo | T. Kaufman | Natalia L. Calvo | Natalia L Calvo | Silvana E Vignaduzzo | Teodoro S Kaufman | R. Maggio
[1] U. Holzgrabe,et al. NMR spectroscopy in pharmaceutical analysis , 2008 .
[2] Srinivasulu Doddaga,et al. Chloroquine-N-oxide, a major oxidative degradation product of chloroquine: identification, synthesis and characterization. , 2013, Journal of pharmaceutical and biomedical analysis.
[3] Neha Parashar,et al. Forced degradation studies to assess the stability of drugs and products , 2013 .
[4] N. Gonnella. LC-NMR: Expanding the Limits of Structure Elucidation , 2013 .
[5] J. M. Babu,et al. Characterization and relative response factor determination of process related impurity in Naproxen by nuclear magnetic resonance spectroscopy. , 2011, Journal of pharmaceutical and biomedical analysis.
[6] P. Umesh,et al. Isolation and structural elucidation of two impurities from a diacerein bulk drug. , 2009, Journal of pharmaceutical and biomedical analysis.
[7] Ashok Kumar,et al. Structural elucidation of process-related impurities in escitalopram by LC/ESI-MS and NMR. , 2010, Journal of pharmaceutical and biomedical analysis.
[8] S. Jacobsson,et al. Quantification of aldehyde impurities in poloxamer by 1H NMR spectrometry , 2005 .
[9] B. Gander,et al. A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation , 1996 .
[10] Andrew Teasdale,et al. Genotoxic Impurities: Strategies for Identification and Control , 2011 .
[11] Andreas M. Abend,et al. Identification of impurities in ivermectin bulk material by mass spectrometry and NMR. , 2006, Journal of pharmaceutical and biomedical analysis.
[12] I. Wilson,et al. On-flow identification of metabolites of paracetamol from human urine using directly coupled CZE–NMR and CEC–NMR spectroscopy , 1998 .
[13] Acharya Subasranjan,et al. An improved validated ultra high pressure liquid chromatography method for separation of tacrolimus impurities and its tautomers. , 2010, Drug testing and analysis.
[14] M. Johansson,et al. Screening of counterfeit corticosteroid in creams and ointments by NMR spectroscopy. , 2012, Journal of pharmaceutical and biomedical analysis.
[15] P. K. Owens,et al. Strategies for the investigation and control of process-related impurities in drug substances. , 2007, Advanced drug delivery reviews.
[16] P. Wei,et al. Identification, Isolation, and Characterization of Impurities in Sodium Tanshinone IIA Sulfonate , 2009 .
[17] L. Tseng,et al. Gradient elution capillary electrochromatography and hyphenation with nuclear magnetic resonance , 1999, Electrophoresis.
[18] G. Vamsi Krishna,et al. Isolation and characterisation of degradant impurities in dipyridamole formulation. , 2012, Journal of pharmaceutical and biomedical analysis.
[19] Jing Luo,et al. HPLC analysis, semi-preparative HPLC preparation and identification of three impurities in salidroside bulk drug. , 2009, Journal of pharmaceutical and biomedical analysis.
[20] Ming Xia,et al. The stability of biapenem and structural identification of impurities in aqueous solution. , 2009, Journal of pharmaceutical and biomedical analysis.
[21] Mario Cindrić,et al. Identification of impurities in acarbose by using an integrated liquid chromatography-nuclear magnetic resonance and liquid chromatography-mass spectrometry approach. , 2005, Journal of separation science.
[22] J. Haginaka,et al. Enantiomeric purity determination of acetyl-L-carnitine by NMR with chiral lanthanide shift reagents. , 2005, Journal of pharmaceutical and biomedical analysis.
[23] M. Gupta,et al. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS. , 2007, Journal of pharmaceutical and biomedical analysis.
[24] Ravi P. Shah,et al. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR. , 2010, Journal of pharmaceutical and biomedical analysis.
[25] Lianming Wu,et al. Structural analysis of photo-degradation in thiazole-containing compounds by LC-MS/MS and NMR. , 2007, Journal of pharmaceutical and biomedical analysis.
[26] N. Nardi,et al. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. , 2008, International journal of pharmaceutics.
[27] S. LaPlante,et al. Quantifying trifluoroacetic acid as a counterion in drug discovery by 19F NMR and capillary electrophoresis. , 2007, Journal of pharmaceutical and biomedical analysis.
[28] Z. Yao,et al. Unified Mechanistic Framework for the Fe(II)-Induced Cleavage of Qinghaosu and Derivatives/Analogues. The First Spin-Trapping Evidence for the Previously Postulated Secondary C-4 Radical , 1998 .
[29] J. Sweedler,et al. Hyphenation of capillary separations with nuclear magnetic resonance spectroscopy. , 2003, Journal of chromatography. A.
[30] D. Mital,et al. Identification of heparin samples that contain impurities or contaminants by chemometric pattern recognition analysis of proton NMR spectral data , 2011, Analytical and bioanalytical chemistry.
[31] W. Ye,et al. Isolation and structure characterization of related impurities in Sodium Tanshinone IIA Sulfonate by LC/ESI-MS(n) and NMR. , 2012, Journal of Pharmaceutical and Biomedical Analysis.
[32] R. Nogueira,et al. Development of a new sodium diclofenac certified reference material using the mass balance approach and ¹H qNMR to determine the certified property value. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[33] Ashok Kumar,et al. Semi-preparative isolation and structural elucidation of an impurity in citalopram by LC/MS/MS. , 2009, Journal of pharmaceutical and biomedical analysis.
[34] H. Nasri,et al. Isolation and Characterization of Cetirizine Degradation Product: Mechanism of Cetirizine Oxidation , 2010, Pharmaceutical Research.
[35] S. Hansen,et al. Identification of reaction products between drug substances and excipients by HPLC-SPE-NMR: ester and amide formation between citric acid and 5-aminosalicylic acid. , 2009, Journal of pharmaceutical and biomedical analysis.
[36] T. Kaufman,et al. Validated stability-indicating HPLC method for the determination of pridinol mesylate. Kinetics study of its degradation in acid medium. , 2008, Journal of pharmaceutical and biomedical analysis.
[37] D. Gorog. Recent Advances in the Impurity Profiling of Drugs , 2008 .
[38] H. Konno,et al. Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. , 2008, Journal of pharmaceutical and biomedical analysis.
[39] D. Greenwood,et al. Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR , 2012, Analytical and Bioanalytical Chemistry.
[40] Z. Béni,et al. New oxidative decomposition mechanism of estradiol through the structural characterization of a minute impurity and its degradants. , 2013, Journal of pharmaceutical and biomedical analysis.
[41] J. Hoogmartens,et al. Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation , 2011, Analytical and Bioanalytical Chemistry.
[42] V. L. Bagirova,et al. Isolation and Identification of Impurities in the Parent Substance of Echinochrome and in the Drug Histochrome , 2004, Pharmaceutical Chemistry Journal.
[43] D. Keire,et al. Analyses of marketplace tacrolimus drug product quality: bioactivity, NMR and LC-MS. , 2013, Journal of pharmaceutical and biomedical analysis.
[44] L. Tseng,et al. Influence of pressure upon coupling pressurized capillary electrochromatography with nuclear magnetic resonance spectroscopy. , 2001, Analytical chemistry.
[45] G. Torri,et al. Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin Preparations , 2001, Seminars in thrombosis and hemostasis.
[46] S. Kumar,et al. LC determination of glimepiride and its related impurities. , 2005, Journal of pharmaceutical and biomedical analysis.
[47] F. Malz,et al. Validation of quantitative NMR. , 2005, Journal of pharmaceutical and biomedical analysis.
[48] P. Jenks,et al. Using high-performance ¹H NMR (HP-qNMR®) for the certification of organic reference materials under accreditation guidelines--describing the overall process with focus on homogeneity and stability assessment. , 2014, Journal of pharmaceutical and biomedical analysis.
[49] D. Kanase,et al. Isolation and characterization of benazepril unknown impurity by chromatographic and spectroscopic methods. , 2006, Journal of pharmaceutical and biomedical analysis.
[50] Vishal D. Shah,et al. Isolation and structure elucidation of major alkaline degradant of ezetimibe. , 2011, Journal of pharmaceutical and biomedical analysis.
[51] N. M. Sekhar,et al. Isolation and characterization of impurities in docetaxel. , 2006, Journal of pharmaceutical and biomedical analysis.
[52] Del Grosso Erika,et al. Forced degradation study of thiocolchicoside: characterization of its degradation products. , 2012, Journal of pharmaceutical and biomedical analysis.
[53] U. Holzgrabe,et al. Impurity profile of amino acids? , 2005, Pharmeuropa scientific notes.
[54] Ashok Kumar,et al. Identification and characterization of process related impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR. , 2009, Journal of pharmaceutical and biomedical analysis.
[55] M. Ilijaš,et al. LC-NMR and LC-MS identification of an impurity in a novel antifungal drug icofungipen. , 2009, Journal of pharmaceutical and biomedical analysis.
[56] V. K. Handa,et al. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride. , 2008, Journal of pharmaceutical and biomedical analysis.
[57] Kazunori Arifuku,et al. Absolute quantitation of stevioside and rebaudioside A in commercial standards by quantitative NMR. , 2013, Chemical & pharmaceutical bulletin.
[58] G. Balogh,et al. The changing role of NMR spectroscopy in off-line impurity identification: A conceptual view , 2006 .
[59] K. G. Prasad,et al. Development and validation of a stability indicating assay of doxofylline by RP-HPLC: ESI-MS/MS, ¹H and ¹³C NMR spectroscopic characterization of degradation products and process related impurities. , 2013, Journal of pharmaceutical and biomedical analysis.
[60] Xiaohong Zhu,et al. Isolation, structural determination, synthesis and quantitative determination of impurities in Intron-A, leached from a silicone tubing. , 2009, Journal of pharmaceutical and biomedical analysis.
[61] M. Haas,et al. The isolation and identification of a toxic impurity in XP315 drug substance. , 2002, Journal of pharmaceutical and biomedical analysis.
[62] S. Sabbah,et al. RP-HPLC and NMR study of cis-trans isomerization of enalaprilat. , 2003, Journal of pharmaceutical and biomedical analysis.
[63] A. Alexander,et al. The design of an on‐line semi‐preparative LC–SPE–NMR system for trace analysis , 2005, Magnetic resonance in chemistry : MRC.
[64] A. Naidu,et al. Isolation, structural elucidation and characterization of impurities in Cefdinir. , 2007, Journal of pharmaceutical and biomedical analysis.
[65] J. Lindon,et al. Impurity profiling in bulk pharmaceutical batches using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements. , 1999, Journal of pharmaceutical and biomedical analysis.
[66] U. Holzgrabe,et al. Quantitative NMR spectroscopy of biologically active substances and excipients , 2010 .
[67] Identification of a Unique Cationic Impurity in Preladenant™ Using Accurate MS and NMR , 2013 .
[68] G. Kalabin,et al. Quantitative nmr spectroscopy for quality control of drugs and pharmaceuticals , 2011, Pharmaceutical Chemistry Journal.
[69] Koichi Saito,et al. Application of high-performance liquid chromatography hyphenated techniques for identification of degradation products of cefpodoxime proxetil. , 2006, Journal of chromatography. A.
[70] J. Wang,et al. Photodegradation of Fleroxacin Injection: Different Products with Different Concentration Levels , 2011, AAPS PharmSciTech.
[71] D. Elder,et al. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. , 2011, Journal of pharmaceutical and biomedical analysis.
[72] E. Antoniadou-Vyza,et al. HPLC analysis, isolation and identification of a new degradation product in carvedilol tablets. , 2008, Journal of pharmaceutical and biomedical analysis.
[73] C. Szántay,et al. Structure of the major degradant of ezetimibe. , 2012, Journal of pharmaceutical and biomedical analysis.
[74] U. Holzgrabe,et al. Determination of free fatty acids in edible oils by 1H NMR spectroscopy , 2012 .
[75] I. A. Revel’skii,et al. Determination of organic impurities in pharmaceutical preparations , 2005 .
[76] Sarfaraz Niazi,et al. Impurities in New Drug Substances , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.
[77] Richard J. Smith,et al. Analysis of drug impurities , 2007 .
[78] R. Linhardt,et al. Structural characterization of heparins from different commercial sources , 2011, Analytical and bioanalytical chemistry.
[79] G. R. Bedford,et al. Preparation and Identification of cis and trans Isomers of a Substituted Triarylethylene , 1966, Nature.
[80] U. Holzgrabe. Quantitative NMR spectroscopy in pharmaceutical applications. , 2010, Progress in nuclear magnetic resonance spectroscopy.
[81] V. K. Handa,et al. Impurity profile study of lopinavir and validation of HPLC method for the determination of related substances in lopinavir drug substance. , 2008, Journal of pharmaceutical and biomedical analysis.
[82] A. Naidu,et al. Structural identification and characterization of impurities in ceftizoxime sodium. , 2007, Journal of pharmaceutical and biomedical analysis.
[83] Neil E. Jacobsen,et al. NMR spectroscopy explained : simplified theory, applications and examples for organic chemistry and structural biology , 2007 .
[84] Kuiwu Wang,et al. Characterization of impurities in semi-synthetic vinorelbine bitartrate by HPLC-MS with mass spectrometric shift technique. , 2005, Journal of pharmaceutical and biomedical analysis.
[85] J. Berridge. Impurities in drug substances and drug products: new approaches to quantification and qualification. , 1995, Journal of pharmaceutical and biomedical analysis.
[86] P. Mourier,et al. Heparin sodium compliance to USP monograph: structural elucidation of an atypical 2.18 ppm NMR signal. , 2012, Journal of pharmaceutical and biomedical analysis.
[87] D. Coleman,et al. Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis. , 2014, Journal of pharmaceutical and biomedical analysis.
[88] M. Jarosinski,et al. HPLC/NMR in Combinatorial Chemistry , 1998 .
[89] R. Nageswara Rao,et al. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study. , 2008, Journal of pharmaceutical and biomedical analysis.
[90] P. Cmoch,et al. Physicochemical characterization of ezetimibe and its impurities , 2011 .
[91] Huibin Zhang,et al. Qualitative and quantitative studies on impurities in G004, a potential hypoglycaemic agent, using liquid chromatography, nuclear magnetic resonance and mass spectrometry. , 2011, Journal of pharmaceutical and biomedical analysis.
[92] A. Mohan,et al. Identification and characterization of a principal oxidation impurity in clopidogrel drug substance and drug product. , 2008, Journal of pharmaceutical and biomedical analysis.
[93] Nafisur Rahman,et al. The importance of impurity analysis in pharmaceutical products: an integrated approach , 2006 .
[94] C. George,et al. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 3. Aromatic amine analogues. , 1990, Journal of medicinal chemistry.
[95] E. Jaroszkiewicz,et al. Radiochemical stability of fluconazole in the solid state. , 2007, Journal of pharmaceutical and biomedical analysis.
[96] C. Szántay,et al. Spectroscopic Methods in Drug Quality Control and Development , 2010 .
[97] I. Wilson,et al. Directly coupled CZE-NMR and CEC-NMR spectroscopy for metabolite analysis: paracetamol metabolites in human urine. , 1998, The Analyst.
[99] J. M. Babu,et al. Structural identification and characterization of potential impurities of pantoprazole sodium. , 2007, Journal of pharmaceutical and biomedical analysis.
[100] Thomas J. Wenzel,et al. Discrimination of Chiral Compounds Using NMR Spectroscopy , 2007 .
[101] M. Malet‐Martino,et al. Quality assessment of fluoxetine and fluvoxamine pharmaceutical formulations purchased in different countries or via the Internet by 19F and 2D DOSY 1H NMR. , 2008, Journal of pharmaceutical and biomedical analysis.
[102] N. Srinivas,et al. Identification and characterization of new impurity in didanosine. , 2007, Journal of pharmaceutical and biomedical analysis.
[103] M. W. Dong,et al. Handbook Of Pharmaceutical Analysis By Hplc , 2008 .
[104] Magali Sautel,et al. Pharmaceutical analysis beyond compendial requirements. , 2005, Journal of separation science.
[105] M. Dreux,et al. A comparative study of commercial liquid chromatographic detectors for the analysis of underivatized amino acids. , 2002, Journal of chromatography. A.
[106] M. Wann. 20 Application of LC-NMR in pharmaceutical analysis , 2005 .
[107] L. Tseng,et al. On-line coupling of capillary electrochromatography, capillary electrophoresis, and capillary HPLC with nuclear magnetic resonance spectroscopy. , 1998, Analytical chemistry.
[108] S. Provera,et al. Application of LC-NMR and HR-NMR to the characterization of biphenyl impurities in the synthetic route development for vestipitant, a novel NK1 antagonist. , 2010, Journal of pharmaceutical and biomedical analysis.
[109] T. Claridge. High-Resolution NMR Techniques in Organic Chemistry , 1999 .
[110] J. Brus,et al. New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations. , 2011, International journal of pharmaceutics.
[111] R. Rupakula,et al. Determination and characterization of degradation products of anastrozole by LC-MS/MS and NMR spectroscopy. , 2011, Journal of pharmaceutical and biomedical analysis.
[112] M. P. Maskarinec,et al. Micellar electrokinetic capillary chromatography , 1986 .
[113] William J. Welsh,et al. Determination of galactosamine impurities in heparin samples by multivariate regression analysis of their 1H NMR spectra , 2011, Analytical and bioanalytical chemistry.
[114] S. Görög,et al. Estimation of impurity profiles in drugs and related materials. , 1998, Journal of pharmaceutical and biomedical analysis.
[115] Mario Cindrić,et al. Identification of unknown impurities in simvastatin substance and tablets by liquid chromatography/tandem mass spectrometry. , 2005, Journal of pharmaceutical and biomedical analysis.
[116] S. Provera,et al. A multi-technique approach using LC-NMR, LC-MS, semi-preparative HPLC, HR-NMR and HR-MS for the isolation and characterization of low-level unknown impurities in GW876008, a novel corticotropin-release factor 1 antagonist. , 2010, Journal of pharmaceutical and biomedical analysis.
[117] Santosh Kumar Bharti,et al. Quantitative 1H NMR spectroscopy , 2012 .
[118] U. Holzgrabe,et al. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[119] R. Mumper,et al. Poly(L-lactic Acid) Microspheres Containing Neutron-Activatable Holmium-165: A Study of the Physical Characteristics of Microspheres Before and After Irradiation in a Nuclear Reactor , 2004, Pharmaceutical Research.
[120] K. Peremans,et al. Impurity profiling quality control testing of synthetic peptides using liquid chromatography-photodiode array-fluorescence and liquid chromatography-electrospray ionization-mass spectrometry: the obestatin case. , 2008, Analytical biochemistry.
[121] Dong-hua Wang,et al. Isolation, synthesis and structure confirmation of the impurity in crude roflumilast product , 2013, Research on Chemical Intermediates.
[122] J. Battiste,et al. 2D 19F/19F NOESY for the assignment of NMR spectra of fluorochemicals , 2004 .
[123] U. Holzgrabe,et al. NMR techniques in biomedical and pharmaceutical analysis. , 2011, Journal of pharmaceutical and biomedical analysis.
[124] Micellar electrokinetic capillary chromatography, high performance liquid chromatography and nuclear magnetic resonance--three orthogonal methods for characterization of critical drugs. , 2004, Journal of pharmaceutical and biomedical analysis.
[125] Haiying Liu,et al. Lessons learned from the contamination of heparin. , 2009, Natural product reports.
[126] L. Tseng,et al. Direct coupling of capillary electrophoresis and nuclear magnetic resonance spectroscopy for the identification of a dinucleotide , 1999 .
[127] Karen M. Alsante,et al. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals , 2003 .
[128] A. Srivastava,et al. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium. , 2008, Journal of pharmaceutical and biomedical analysis.
[129] K. Albert,et al. Online coupling of gas chromatography to nuclear magnetic resonance spectroscopy: method for the analysis of volatile stereoisomers. , 2008, Analytical chemistry.
[130] A. Rück,et al. Using high-performance quantitative NMR (HP-qNMR®) for certifying traceable and highly accurate purity values of organic reference materials with uncertainties <0.1 % , 2013, Accreditation and Quality Assurance.
[131] Ashok Kumar,et al. Application of GC-EI-MS for the identification and investigation of positional isomer in primaquine, an antimalarial drug. , 2005, Journal of pharmaceutical and biomedical analysis.
[132] Ravi P. Shah,et al. Identification and characterization of a photolytic degradation product of telmisartan using LC-MS/TOF, LC-MSn, LC-NMR and on-line H/D exchange mass studies. , 2010, Journal of pharmaceutical and biomedical analysis.
[133] R. N. Rao,et al. Chapter 19 – Monitoring of Process Impurities in Drugs , 1998 .
[134] D. Satheesh,et al. Identification, isolation and characterization of process related impurities in ezetimibe. , 2014, Journal of pharmaceutical and biomedical analysis.
[135] Jacek Namieśnik,et al. LC-MS and LC-NMR as Complementary Techniques for the Determination of Pharmaceuticals in Dosage Formulations , 2013 .
[136] U. Holzgrabe,et al. Quantitative NMR spectroscopy--applications in drug analysis. , 2005, Journal of pharmaceutical and biomedical analysis.
[137] K. Albert. On-line LC-NMR and related techniques , 2002 .
[138] Caitlin M Sullivan,et al. Photosensitized degradation of losartan potassium in an extemporaneous suspension formulation. , 2006, Journal of pharmaceutical and biomedical analysis.
[139] Ashok Kumar,et al. Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR. , 2010, Journal of pharmaceutical and biomedical analysis.
[140] M. Malet‐Martino,et al. Generic ciprofloxacin tablets contain the stated amount of drug and different impurity profiles: A 19F, 1H and DOSY NMR analysis. , 2007, Journal of pharmaceutical and biomedical analysis.
[141] D. Colombo,et al. Evaluation, synthesis and characterization of tacrolimus impurities , 2012, The Journal of Antibiotics.
[142] J. Guan,et al. A multidisciplinary approach to identify a degradation product in a pharmaceutical dosage form. , 2011, Journal of Pharmaceutical and Biomedical Analysis.
[143] D. Armstrong,et al. Enantiomeric impurities in chiral synthons, catalysts, and auxiliaries. Part 3. , 2006, Tetrahedron, asymmetry.
[144] Guido F Pauli,et al. Quantitative 1H NMR. Development and potential of an analytical method: an update. , 2012, Journal of natural products.
[145] J. Klimeš,et al. HPLC-DAD and MS/MS analysis of novel drug candidates from the group of aromatic hydrazones revealing the presence of geometric isomers. , 2008, Journal of pharmaceutical and biomedical analysis.
[146] R. N. Rao,et al. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy. , 2009, Journal of pharmaceutical and biomedical analysis.
[147] F. Kusu,et al. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial amlodipine maleate tablets. , 2008, Journal of chromatography. A.
[148] J. Saurina,et al. Potentiality of proton nuclear magnetic resonance and multivariate calibration methods for the determination of dermatan sulfate contamination in heparin samples. , 2000, The Analyst.
[149] F. Malz,et al. Structure analytical methods for quantitative reference applications , 2005 .
[150] R. C. Moreton. United States Pharmacopeia-National Formulary , 2016 .
[151] S. Ahuja. Assuring quality of drugs by monitoring impurities. , 2007, Advanced drug delivery reviews.
[152] P. Novak,et al. The application of LC-NMR and LC-MS for the separation and rapid structure elucidation of an unknown impurity in 5-aminosalicylic acid. , 2006, Journal of pharmaceutical and biomedical analysis.
[153] H. Naoki,et al. Photo-degradation products of pramipexole. , 2012, Bioorganic & medicinal chemistry letters.
[154] K. Holme,et al. Monitoring the purity of pharmaceutical heparin preparations by high-field 1H-nuclear magnetic resonance spectroscopy. , 1989, Journal of pharmaceutical sciences.
[155] U. Holzgrabe,et al. Alternatives to amino acid analysis for the purity control of pharmaceutical grade L-alanine. , 2010, Journal of separation science.
[156] A. Wand,et al. Optimal Use of Cryogenic Probe Technology in NMR Studies of Proteins , 2000 .
[157] U. Holzgrabe,et al. Determination of free fatty acids in pharmaceutical lipids by ¹H NMR and comparison with the classical acid value. , 2014, Journal of pharmaceutical and biomedical analysis.
[158] Richard L. Magin,et al. Nanoliter Volume Sample cells for 1H NMR: Application to Online Detection in Capillary Electrophoresis , 1994 .
[159] S. Bari,et al. Impurity profile: Significance in Active Pharmaceutical Ingredient , 2007 .
[160] J. V. Rompay. Purity determination and evaluation of new drug substances. , 1986 .
[161] T. Arvidsson,et al. Use and qualification of primary and secondary standards employed in quantitative ¹H NMR spectroscopy of pharmaceuticals. , 2014, Journal of pharmaceutical and biomedical analysis.
[162] A. Mazzanti,et al. Identification of an isomer impurity in piperaquine drug substance. , 2006, Journal of chromatography. A.
[163] C. Larive,et al. Analysis and characterization of heparin impurities , 2010, Analytical and bioanalytical chemistry.
[164] R. Pazdur,et al. Approval Summary for Bortezomib for Injection in the Treatment of Multiple Myeloma , 2004, Clinical Cancer Research.
[165] F. Corana,et al. LC-MS characterization of trace impurities contained in calcium folinate. , 2005, Journal of pharmaceutical and biomedical analysis.
[166] J. Galambos,et al. NMR and mass spectrometric characterization of vinblastine, vincristine and some new related impurities--part II. , 2013, Journal of pharmaceutical and biomedical analysis.
[167] J. Saurina,et al. Proton nuclear magnetic resonance characterisation of glycosaminoglycans using chemometric techniques. , 2002, The Analyst.
[168] J. M. Babu,et al. Identification and characterization of potential impurities of rabeprazole sodium. , 2007, Journal of pharmaceutical and biomedical analysis.
[169] D. Vir,et al. Identification, synthesis and characterization of an unknown process related impurity in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI–IT/MS, 1H, 13C and 1H–1H COSY NMR , 2013, Journal of pharmaceutical analysis.
[170] E. Yashima,et al. NMR Studies of Chiral Discrimination Relevant to the Liquid Chromatographic Enantioseparation by a Cellulose Phenylcarbamate Derivative , 1996 .
[171] A. Krstulović,et al. Defining drug purity through chromatographic and related methods: current status and perspectives. , 1997, Journal of chromatography. B, Biomedical sciences and applications.
[172] J. Keeler. Understanding NMR Spectroscopy , 2005 .
[173] Karen M. Alsante,et al. Tools and workflow for structure elucidation of drug degradation products , 2013 .
[174] K. Albert,et al. Online coupling of enantioselective capillary gas chromatography with proton nuclear magnetic resonance spectroscopy. , 2010, Chirality.
[175] Yuanchao Li,et al. Characterization of related impurities in megestrol acetate. , 2006, Journal of pharmaceutical and biomedical analysis.
[176] Ashok Kumar,et al. Isolation and structural identification of an impurity in fluconazole bulk drug substance. , 2007, Journal of pharmaceutical and biomedical analysis.
[177] G. Balogh,et al. Estimation of impurity profiles of drugs and related materials: part XXI. HPLC/UV/MS study of the impurity profile of ethynodiol diacetate. , 2002, Journal of pharmaceutical and biomedical analysis.
[178] What is the degradation product of ezetimibe? , 2011, Journal of pharmaceutical and biomedical analysis.
[179] H. van de Velde,et al. Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile , 2011, AAPS PharmSciTech.
[180] P. K. Basniwal,et al. Forced degradation and impurity profiling: recent trends in analytical perspectives. , 2013, Journal of pharmaceutical and biomedical analysis.
[181] S. Görög. Identification and determination of impurities in drugs , 2000 .
[182] P. Schmieder,et al. Conformational Analysis of the cis‐ and trans‐Isomers of FK506 by NMR and Molecular Dynamics , 1991 .
[183] E. Brenna,et al. Isolation and characterisation of a phenolic impurity in a commercial sample of duloxetine. , 2007, Journal of pharmaceutical and biomedical analysis.
[184] D. Armstrong,et al. Enantiomeric impurities in chiral catalysts, auxiliaries, synthons and resolving agents. Part 2 , 1999 .
[185] B. Segmuller,et al. Identification of autoxidation and photodegradation products of ethynylestradiol by on-line HPLC-NMR and HPLC-S. , 2000, Journal of pharmaceutical and biomedical analysis.
[186] S. Berger,et al. 50 and More Essential NMR Experiments: A Detailed Guide , 2013 .
[187] H. Sharma,et al. Identification, isolation and characterization of process-related impurities in Rizatriptan benzoate. , 2009, Journal of Pharmaceutical and Biomedical Analysis.
[188] U. Holzgrabe,et al. 1H-NMR Spectroscopy as a New Tool in the Assessment of the Oxidative State in Edible Oils , 2012 .
[189] A. Berthod. Chiral Recognition in Separation Methods , 2010 .
[190] S. Ahuja. Impurities evaluation of pharmaceuticals , 1998 .
[191] T. Kaufman,et al. Development and validation of an HPLC method for the determination of process-related impurities in pridinol mesylate, employing experimental designs. , 2009, Analytica chimica acta.
[192] C. B'hymer,et al. Residual Solvent Testing: A Review of Gas-Chromatographic and Alternative Techniques , 2003, Pharmaceutical Research.
[193] I. Singh,et al. Determining and reporting purity of organic molecules: why qNMR , 2013, Magnetic resonance in chemistry : MRC.
[194] Zuzana Mandelová,et al. Identification, preparation and UHPLC determination of process-related impurity in zolmitriptan. , 2012, Journal of pharmaceutical and biomedical analysis.
[195] D. Armstrong,et al. Enantiomeric impurities in chiral catalysts, auxiliaries, and synthons used in enantioselective syntheses. Part 4 , 1998 .
[196] G. Bertho,et al. A new derivative detected in accelerated ageing of artesunate-amodiaquine fixed dose combination tablets. , 2013, Journal of pharmaceutical and biomedical analysis.
[197] J. McAlpine,et al. Design of countercurrent separation of Ginkgo biloba terpene lactones by nuclear magnetic resonance. , 2012, Journal of chromatography. A.
[198] M. Yoshikawa,et al. Development and testing of superfluid-cooled 900 MHz NMR magnet , 2001 .
[199] B. Pramanik,et al. Structural characterization of the oxidative degradation products of an antifungal agent SCH 56592 by LC-NMR and LC-MS. , 2001, Journal of pharmaceutical and biomedical analysis.
[200] R. Mukherjee,et al. Isolation and characterization of degradation impurities in docetaxel drug substance and its formulation. , 2007, Journal of pharmaceutical and biomedical analysis.
[201] J. Battiste,et al. Applications of 19F multidimensional NMR , 2006 .
[202] Sarfaraz Niazi,et al. Impurities in New Drug Products , 2016 .
[203] T. Schoenberger. Determination of standard sample purity using the high-precision 1H-NMR process , 2012, Analytical and Bioanalytical Chemistry.
[204] S. Parapini,et al. The Fe2+‐Mediated Decomposition, PfATP6 Binding, and Antimalarial Activities of Artemisone and Other Artemisinins: The Unlikelihood of C‐Centered Radicals as Bioactive Intermediates , 2007, ChemMedChem.
[205] G. Tárkányi,et al. Quantitative approach for the screening of cyclodextrins by nuclear magnetic resonance spectroscopy in support of chiral separations in liquid chromatography and capillary electrophoresis enantioseparation of norgestrel with alpha-, beta- and gamma-cyclodextrins. , 2002, Journal of chromatography. A.
[206] Jingqi Huang,et al. Identification of adulterants in a Chinese herbal medicine by LC-HRMS and LC-MS-SPE/NMR and comparative in vivo study with standards in a hypertensive rat model. , 2010, Journal of pharmaceutical and biomedical analysis.
[207] A. Vannacci,et al. Combined HPLC-DAD-MS, HPLC-MS(n) and NMR spectroscopy for quality control of plant extracts: the case of a commercial blend sold as dietary supplement. , 2014, Journal of pharmaceutical and biomedical analysis.
[208] T. Kaufman,et al. Characterization of two new potential impurities of Valsartan obtained under photodegradation stress condition. , 2011, Journal of pharmaceutical and biomedical analysis.
[209] G. Pauli,et al. Purification of berry flavonol glycosides by long-bed gel permeation chromatography. , 2012, Journal of chromatography. A.
[210] Richard J. Smith,et al. Use of liquid chromatography-nuclear magnetic resonance spectroscopy for the identification of impurities in drug substances , 1994 .
[211] H. Avdovich,et al. Nuclear magnetic resonance identification and estimation of solvent residues in cocaine , 1991 .
[212] T. Wenzel,et al. Using NMR spectroscopic methods to determine enantiomeric purity and assign absolute stereochemistry. , 2011, Progress in nuclear magnetic resonance spectroscopy.
[213] A. Mohan,et al. Identification, Isolation, and Characterization of Five Potential Degradation Impurities in Candesartan Cilexetil Tablets , 2009 .
[214] D. Greenwood,et al. Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR. , 2012, Journal of pharmaceutical and biomedical analysis.
[215] Jimmy D. Bell,et al. Modern Magnetic Resonance , 2006 .
[216] Karen M. Alsante,et al. Degradation and Impurity Analysis for Pharmaceutical Drug Candidates , 2011 .
[217] Isolation, structure characterization and quantification of related impurities in asperosaponin VI. , 2013, Chinese journal of natural medicines.
[218] S. Baertschi. Analytical methodologies for discovering and profiling degradation-related impurities , 2006 .
[219] D. Keire,et al. Characterization of currently marketed heparin products: key tests for LMWH quality assurance. , 2013, Journal of pharmaceutical and biomedical analysis.
[220] E. Brenna,et al. Isolation and characterisation of impurities in adapalene. , 2007, Journal of pharmaceutical and biomedical analysis.
[221] R Nageswara Rao,et al. An overview of the recent trends in development of HPLC methods for determination of impurities in drugs. , 2003, Journal of pharmaceutical and biomedical analysis.
[222] Ravi P. Shah,et al. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. , 2012, Journal of pharmaceutical and biomedical analysis.
[223] Ravi P. Shah,et al. Identification and characterization of geometrical isomeric photo degradation product of eprosartan using LC-MS and LC-NMR , 2011 .
[224] Michal Douša,et al. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold. , 2011, Journal of pharmaceutical and biomedical analysis.
[225] Lucinda F Buhse,et al. Combining (1)H NMR spectroscopy and chemometrics to identify heparin samples that may possess dermatan sulfate (DS) impurities or oversulfated chondroitin sulfate (OSCS) contaminants. , 2011, Journal of pharmaceutical and biomedical analysis.
[226] S. Zeng,et al. Identification and characterization of four process-related impurities in retigabine. , 2012, Journal of pharmaceutical and biomedical analysis.
[227] Fengqing Yang,et al. Development of a simple and stability-indicating RP-HPLC method for determining olanzapine and related impurities generated in the preparative process. , 2011, The Analyst.
[228] M. Bernstein,et al. Enantiomeric purity determination by NMR: proving the purity of a single enantiomer , 2013 .
[229] Cuirong Sun,et al. Separation and characterization of synthetic impurities of triclabendazole by reversed-phase high-performance liquid chromatography/electrospray ionization mass spectrometry. , 2005, Journal of pharmaceutical and biomedical analysis.